CRESCENT BIOPHARMA, INC. (CBIO) Free cash flow 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$72.5MFY2025 · since FY2016: -$30.4M → -$72.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$72.5M | -132.9% |
| FY2024 | -$31.1M | +10.9% |
| FY2023 | -$34.9M | +25.0% |
| FY2022 | -$46.5M | +19.1% |
| FY2021 | -$57.5M | -46.3% |
| FY2020 | -$39.3M | +24.6% |
| FY2019 | -$52.1M | -20.0% |
| FY2018 | -$43.5M | -44.6% |
| FY2017 | -$30.1M | +1.2% |
| FY2016 | -$30.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net incomeCBIO Net marginCBIO Gross profitCBIO Gross marginCBIO Operating incomeCBIO Operating marginCBIO Operating cash flowCBIO Capital expendituresCBIO Return on equityCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →